FIELD: medicine.
SUBSTANCE: claimed invention relates to medicine, in particular to materials permitting to stop hemorrhage during operational intrusions. Material contains thrombocyte concentrate unsuitable for transfusion, cryoprecipitate of blood plasma proteins in ratio 1:1, as well as calcium chloride in amount 0.05 ml per 1 ml of mixture of thrombocyte concentrate with cryoprecipitate and thrombin in amount 0.01 NIH units per 1 ml of mixture of thrombocyte concentrate with cryoprecipitate.
EFFECT: claimed invention ensures increase of concentration of blood coagulation activators and factors in hemostatic material in order to increase its hemotatic activity.
| Title | Year | Author | Number | 
|---|---|---|---|
| HEMOSTATIC MATERIAL | 2005 | 
 | RU2287333C1 | 
| ORGAN-SPECIFIC REGENERANT GI | 2011 | 
 | RU2462255C1 | 
| HAEMOSTATIC SPONGE AND METHOD FOR ITS PREPARATION | 2016 | 
 | RU2618896C1 | 
| HEMOSTATIC COATING IN THE FORM OF POWDER | 2017 | 
 | RU2660582C1 | 
| HAEMOSTATIC SPONGE | 2011 | 
 | RU2562569C2 | 
| HEMOSTATIC SPONGE AND METHOD OF ITS PRODUCTION | 2016 | 
 | RU2628809C1 | 
| METHOD OF DETERMINING INDICATIONS FOR TRANSFUSION OF PLASMA-COAGULATION HAEMOSTASIS CORRECTORS IN CARDIAC SURGERY | 2014 | 
 | RU2568581C1 | 
| METHOD FOR ENDOSCOPIC STOP OF GASTROINTESTINAL BLEEDING | 2016 | 
 | RU2632771C1 | 
| METHOD OF PREPARATION OF AUTOLOGOUS TWO-COMPONENT FIBRIN ADHESIVE | 2019 | 
 | RU2704256C1 | 
| FACTOR II AND FIBRINOGEN FOR TREATMENT OF HAEMOSTATIC DISORDERS | 2011 | 
 | RU2606155C2 | 
Authors
Dates
2009-05-10—Published
2008-02-19—Filed